TILs have been shown to be associated with improved outcomes in HER2-positive breast cancer patients treated with adjuvant chemotherapy in the BIG 02–98 trial7 as well as an abbreviated course of trastuzumab and adjuvant chemotherapy in the FinHER trial8. The gene discussed is ERBB2; the disease is breast cancer.